For research teamsFind studies
Back to all studies
CompletedNCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

This study is completed. It focuses on schizophrenia and currently lists study information in Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, the Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.

SchizophreniaOtherOver 18 Years
In plain English

Key information made simple

This study exists to understand whether the medication Flexibly is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication Flexibly in practice and what may need to be adjusted. For people living with Schizophrenia, small gains in stability can make a meaningful difference over time. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT00460512. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Belgium.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Janssen-Cilag International NV
Sponsor type
Unknown or unclear
Main activity
medication or study treatment
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Completed
Source
Official registry link
FAQ

Questions about this study

What is An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Janssen-Cilag International NV. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Related studies

Other studies you may want to explore next

An Efficacy, Safety And Tolerability Study of. — Schizophrenia Clinical Trial | HopeStage